MGMT and glioblastoma: According to data from a randomized phase 3 trial involving 573 patients with newly diagnosed glioblastoma who received radiotherapy alone or with concomitant and adjuvant temozolomide, MGMT promoter methylation is a strong predictor of benefit from temozolomide chemotherapy [32].